Liver disease (acute hepatitis, Chronic hepatitis, liver cirrhosis, hepatic failure, etc) Liver tumor (hepatocellular carcinoma, cholangiocellular carcinoma, metastatic liver tumor, etc)
Conditions
Interventions
1. Patients with liver disease, who can admit to our hospital 2. we used 25 % stable Xe gas in conjunction with an AZ-726 Xe gas inhalation system (Anzai Medical, Tokyo, Japan). The wash-in and wash-
Sponsors
St. Marianna University, School of Medicine, Department of Internal Medicine, Division of Gastroenterology & Hepatology
Anzai Medical Company Ltd
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inpatients with liver disease or tumor
Exclusion criteria
Exclusion criteria: 1. severe cardiac, renal and lung disease 2. consciouness distubance 3. severe allergy and asthma 4. pregnacy 5. Otherwise, in case that investigators judge the patient who is inappropriate for this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. correlation between tissue blood flow and stage of fibrosis. 2. correlation between tissue blood flow and grade of Child-Pugh. 3. correlation between Xe solubility coefficient and stage of steatosis. 4. Alteration of tissue blood flow and Xe solubility coefficient before and after treatment (interferon, endoscopic procedure, operation, diet-exercise therapy, etc) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. reproducibility 2. safety | — |
Countries
Japan
Contacts
Public ContactHideaki Takahashi
St. Marianna University, School of Medicine Department of Internal Medicine, Division of Gastroenterology
Outcome results
None listed